Legrand recently announced the publication of research showing its Kenall Indigo‑Clean light disinfection technology effectively and safely inactivates SARS-CoV-2 and influenza A viruses in a range of real-world clinical settings. The study was published in partnership with the Icahn School of Medicine at Mount Sinai.

The paper, “The virucidal effects of 405 nm visible light on SARS-CoV-2 and influenza A virus,” was published in Scientific Reports on September 30, 2021. It reflects how researchers evaluated the inactivation rate of the SARS-CoV-2 virus using 405 nm visible light under a range of clinical conditions. Kenall then applied these findings to a real-world usage model and determined that Indigo-Clean would achieve a SARS-CoV-2 inactivation rate of 94% based on 12 hours of occupied room use and 12 hours of unoccupied room use. The study was funded by Kenall.

The potential of specific wavelengths within the electromagnetic spectrum is an area of growing clinical interest. Ultraviolet (UV) technologies have demonstrated the ability to reduce virological spread, but potential toxicities have limited its use in occupied spaces. Longer wavelengths with less irradiation energy such as visible light (405 nanometers) have largely been evaluated in bactericidal and fungicidal applications. This research offers new evidence that lower-risk 405 nm visible light can inactivate the SARS-CoV-2 and influenza A viruses.